Allergenicity and Toxicity Platform

The Bioinformatics Institute (BII) develops computational tools to assess the safety of proteins. Our established platform, AllerCatPro 2.0, assesses allergenic potential by comparing protein sequences and three-dimensional structures with those of known allergens. This approach helps address limitations of methods that rely on sequence similarity alone.

AllerCatPro Enzyme is a standalone software package licensed for offline analysis, including function for user-specific database for comparison.

AllerCatToxin is a complementary protein toxicity capability under further development with SFA and IMCB through the SFS proteomics project.

 

Key Services

  • AllerCatPro 2.0 allergenicity assessment:
    • We assess submitted protein sequences against curated allergen data from WHO/IUIS, COMPARE, FARRP, UniProtKB and Allergome.
    • Clients receive an Excel report and summary table covering predicted allergenic potential, potential cross-reactivity based on similarity in sequences and protein 3D structure to known allergens, protein information (Uniprot/NCBI), functionality (Pfam, InterPro, SUPFAM), as well as clinical relevance with regards to IgE prevalence and allergen information related to the most similar allergen.
    • A consultancy package is available to help clients interpret the results.
  • AllerCatPro Enzyme
    • Compare submitted enzyme sequences with reference enzymes, including a client’s proprietary sequences when provided.
    • Identify the closest matches and link them to available safety information in client-provided databases.
    • Tailor the analysis and reporting to the client’s enzyme portfolio and assessment needs.
  • AllerCatToxin toxicity assessment
    • Computational screening of submitted protein sequences to identify potential toxicity concerns through comparison with curated reference proteins and available toxicity-related information.
    • Identification and prioritisation of proteins showing potential toxicity-related similarities for further safety assessment.
    • Provision of sequence-level screening reports, including predicted similar toxin proteins, sequence similarity, functional annotations and supporting information to facilitate interpretation and subsequent experimental validation.

 

Key Applications

  • AllerCatPro
    • Any confidential protein sequences, full transcriptome, or proteome in FASTA format can be used as input.
    • Industry users processing large batches (> 50 sequences) because AllercatPro 2.0 server only allow up to 50 sequences input/ time.
    • Amino acid sequences obtained from mass spectrometry of alternative proteins or novel food sources.
    • Note: Artificially designed or engineered proteins as well as industrial enzymes, etc. are currently outside of the applicability domain of AllerCatPro.
       

      AllerCatPro 2.0 #1 Figure 1: AllerCatPro 2.0

      AllerCatPro 2.0 #2 Figure 2: Input and output of AllerCatPro 2.0

  • AllerCatPro Enzyme
    • Compare a new enzyme candidate with enzymes in a company’s proprietary database.
    • Review available safety data for similar enzymes to support early development decisions.
    • Assess candidates in emerging enzyme classes for which established assessment methods are limited.
    • Note: The tool’s safety interpretation depends on the data supplied by the client. Without relevant safety data, it provides sequence similarity results but cannot establish enzyme safety.
       

      AllerCatPro Enzyme Figure 3: AllerCatPro Enzyme

      Customisable AllerCatPro Enzyme Figure 4: Customisable AllerCatPro Enzyme

  • AllerCatToxin
    • Preliminary toxicity screening of proteins from novel foods, alternative proteins, and fermentation-derived products.
    • Identification and prioritisation of proteins with potential toxicity-related similarities from proteomic and protein sequence datasets.
    • Supporting food safety assessment through integrated computational screening of protein allergenicity and toxicity using AllerCatPro and AllerCatToxin.
    • Note: AllerCatToxin is currently undergoing further development and validation in collaboration with SFA and IMCB under the SFS proteomic project. Its computational screening results provide preliminary evidence and should not be interpreted as definitive confirmation of protein toxicity or safety.
       
      AllerCatToxin Figure 5: AllerCatToxin

 

Our People

Dr. Vachiranee Limviphuvadh
Dr. Minh N. Nguyen

Key team members: Dr. Vachiranee Limviphuvadh leads AllerCatPro analyses, and Dr. Minh N. Nguyen leads AllerCatToxin analyses. Both collaborate on AllerCatPro Enzyme.

 

For more information or collaboration inquiries, please contact us at allercatpro@a-star.edu.sg.